On June 27, 2014, EDAP TMS S.A. (ADR) (NASDAQ:EDAP) announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP’s manufacturing site with no findings nor issuance of Form 483 observations. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) net profit margin is -1.40% and weekly performance is 23.82%. On last trading day company shares ended up $5.25. Analysts mean target price for the company is $6.00. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) distance from 50-day simple moving average (SMA50) is 48.18%.
On June 19, 2014, Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies – KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Nektar Therapeutics (NASDAQ:NKTR) shares advanced 5.14% in last trading session and ended the day on $13.47. NKTR Gross Margin is 76.10% and its return on assets is -35.70%. Nektar Therapeutics (NASDAQ:NKTR) quarterly performance is 6.57%.
On June 3, 2014, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the results of a cost analysis study that showed the use of intravenous patient-controlled analgesia, IV PCA, can typically cost a health system more than $200 in opioid drug and IV PCA equipment costs per patient over a typical 2-day postoperative in-hospital stay. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) shares moved up 5.95% in last trading session and was closed at $10.86, while trading in range of $10.22 – $10.94. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) year to date (YTD) performance is -3.98%.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are surging this afternoon, up 6.64 to $301.23, after Sanofi increased its stake in the biopharmaceutical firm although it has said it doesn’t plan to buy the company, according to the Wall Street Journal. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) ended the last trading day at $303.39. Company weekly volatility is calculated as 3.89% and price to cash ratio as 47.22. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) showed a positive weekly performance of 9.09%.
On June 30, 2014, IGI Laboratories, Inc. (NYSEMKT:IG), has been added as a member of the broad-market Russell 3000® Index after the equity markets closed on June 27 as Russell Investments reconstituted its comprehensive family of global indexes. IGI Laboratories, Inc. (NYSEMKT:IG) shares moved up 7.91% in last trading session and was closed at $5.73, while trading in range of $5.28 – $5.90. IGI Laboratories, Inc. (NYSEMKT:IG) year to date (YTD) performance is 87.87%.